Akari Therapeutics Plc — $1.83M Form D filing, June 2026

What the filing says

• Offered: $5,500,000. Sold: $1,833,333. Left to sell: $3,666,667. (filing)
• Investors: 6 had already invested. (filing)
• Date of first sale: May 20, 2026. (filing)
• Types of securities: Options, warrants or other rights to acquire another security; Securities to be acquired on exercise of an option, warrant or other right; Other: American Depositary Shares (ADSs), each representing 80,000 Ordinary Shares. (filing)
• Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters. It adds: “The Company intends to use the net proceeds for working capital and general corporate purposes.” (filing)
• On the amounts offered and sold: the filing adds “Offering of ADSs, Pre-Funded Warrants, Series H, I and J Warrants, each convertible into one ADS for $5,500,000. Approximately $1,833,333 raised to date. The issuance of Series Warrants are subject to shareholder approval.” (filing)
• On sales commissions and finders' fees: the filing adds “Paulson is also entitled to a fee equal to 2.0% of the gross proceeds, a non-accountable expense of $15,000, and 117,647 Placement Agent ADSs. The issuance of the Placement Agent ADSs are subject to receipt of shareholder approval.” (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on Akari Therapeutics Plc See pricing